Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc.（RCKT）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
rckt · 股价预测 · 19 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 19 位华尔街分析师
Buy
19 位分析师
共识
评级分布
12 个月目标价
High
$5.00
Consensus
$5.00
+85.2% upside
Low
$5.00
Median: $5 · Last Close: $2.70
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
短期股价预测
Low Activity算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.57 | ↓ 4.71% |
1-day model range: $2.53–$2.61. Peak: $2.61 (-4.71%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | -35.3% |
| 2028 | — | -46.8% |
| 2029 | — | -51.5% |
| 2030 | — | -53.6% |
| 2031 | — | -54.6% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · RCKT · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-11 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-30 | B of A Securities | Maintains | Buy→Buy |
| 2026-03-27 | Chardan Capital | Maintains | Buy→Buy |
| 2026-03-02 | Goldman Sachs | Maintains | Sell→Sell |
| 2026-02-27 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-11-18 | B of A Securities | Maintains | Buy→Buy |
| 2025-11-18 | JP Morgan | Downgrade ↓ | Overweight→Underweight |
| 2025-10-14 | Chardan Capital | Maintains | Buy→Buy |
| 2025-10-03 | Leerink Partners | Maintains | Market Perform→Market Perform |
| 2025-08-20 | B of A Securities | Upgrade ↑ | Neutral→Buy |
Wall Street analysts have recently issued updated ratings on Rocket Pharmaceuticals, Inc. (RCKT) stock. Of the recent 104 rating actions, 1 were upgrades and 7 were downgrades. 19 analysts currently cover RCKT.
分析师推荐趋势
RCKT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$2M
↓ 96.5% YoY
Revenue Next Year
$20M
↑ 765.4% YoY
EPS This Year
$-0.28
EPS Next Year
$-1.27
↑ 362.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast RCKT EPS of $-0.28 for the current fiscal year, based on estimates from 9 analysts. The RCKT revenue forecast is $2M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
RCKT 股价预测由两类独立数据源支撑：来自 19 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。RCKT 的共识目标价为 $5.00（+85.2% 上行空间），分析师共识为 Buy。
RCKT 的短期预测（明日）为 $2.57（-4.71%）。 RCKT 对 2030 年的预测区间为 $1–$1。
Rocket Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 RCKT。RCKT 在 2027 年的整体展望偏积极，在覆盖分析师中约 68% 对应 Buy 共识。
常见问题
RCKT 预测 · 8 个问题根据 19 位华尔街分析师，RCKT 的 12 个月平均目标价为 $5.00，最高 $5.00、最低 $5.00。若有图表，中位目标价可在上方查看。相对当前价 $2.70，隐含约 +85.2% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.